The structure of glycosaminoglycans and their interactions with proteins

Chemical Biology and Drug Design

Volumn 72, Issue 6, 2008, Pages 455-482

  Gandhi, Neha S ^a   Mancera, Ricardo L ^a  

^a CURTIN UNIVERSITY   (Australia)

Author keywords

Carbohydrates; Chondroitin sulphate; Dermatan sulphate; Glycosaminoglycans; Heparan sulphate; Heparin; Hyaluronic acid; Keratan sulphate; Proteoglycans

Indexed keywords

ACIDIC FIBROBLAST GROWTH FACTOR; AMYLOID P COMPONENT; ANTITHROMBIN; BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 10A; CELL ADHESION MOLECULE; CHONDROITIN SULFATE; CYTOKINE; DERMATAN SULFATE; FIBROBLAST GROWTH FACTOR RECEPTOR 1; FIBROBLAST GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; GLYCOPROTEIN GP 120; GLYCOSAMINOGLYCAN; GROWTH FACTOR; HEPARIN; HYALURONIC ACID; INTERLEUKIN 8; KERATAN SULFATE; LIPOCORTIN 2; LIPOCORTIN 5; METAL ION; NERVE CELL ADHESION MOLECULE; PLEIOTROPHIN; PROTEOGLYCAN; RANTES; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; THROMBIN; THROMBOCYTE FACTOR 4; UNINDEXED DRUG;

BINDING AFFINITY; BINDING SITE; CARBOHYDRATE ANALYSIS; COMPLEX FORMATION; CONFORMATIONAL TRANSITION; MOLECULAR MODEL; PH; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; REVIEW;

ANTITHROMBIN III; CHONDROITIN SULFATES; COMPUTER SIMULATION; GLYCOSAMINOGLYCANS; HEPARITIN SULFATE; HYALURONIC ACID; HYDROGEN-ION CONCENTRATION; KERATAN SULFATE; METALS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; THERMODYNAMICS;

EID: 56649100319     PISSN: 17470277     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2008.00741.x     Document Type: Review

References (232)

1. Rademacher T.W., Parekh R.B., Dwek R.A. (1988) Glycobiology. Annu Rev Biochem 57 : 785 838.
2. Jackson R.L., Busch S.J., Cardin A.D. (1991) Glycosaminoglycans: molecular properties, protein interactions, and role in physiological processes. Physiol Rev 71 : 481 539.
3. Casu B., Lindahl U. (2001) Structure and biological interactions of heparin and heparan sulfate. Adv Carbohydr Chem Biochem 57 : 159 206.
4. Conrad H.E. (1998) Heparin-Binding Proteins. San Diego, CA : Academic Press.
5. Champe P.C., Harvey R.A. (1994) Biochemistry (Lippincott's Illustrated Reviews). Philadelphia, PA : Lippincott-Raven.
6. Sasisekharan R., Venkataraman G. (2000) Heparin and heparan sulfate: biosynthesis, structure and function. Curr Opin Chem Biol 4 : 626 631.
7. Capila I., Linhardt R.J. (2002) Heparin-protein interactions. Angew Chem Int Ed Engl 41 : 390 412.
8. Sharon N. (1986) IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycoproteins, glycopeptides and peptidoglycans. Recommendations 1985. Eur J Biochem 159 : 1 6.
9. Lawrence R., Lu H., Rosenberg R.D., Esko J.D., Zhang L. (2008) Disaccharide structure code for the easy representation of constituent oligosaccharides from glycosaminoglycans. Nat Methods 5 : 291 292.
10. Bohne-Lang A., Lang E., Förster T., von der Lieth C.-W. (2001) LINUCS: LInear Notation for Unique description of Carbohydrate Sequences. Carbohydr Res 336 : 1 11.
11. Banin E., Neuberger Y., Altshuler Y., Halevi A., Inbar O., Dotan N. et al. (2002) A novel linear code nomenclature for complex carbohydrates. Trends Glycosci Glycotechnol 14 : 127 137.
12. Itano N. (2008) Simple primary structure, complex turnover regulation and multiple roles of hyaluronan. J Biochem 144 : 131 137.
13. Toole B.P. (1997) Hyaluronan in morphogenesis. J Intern Med 242 : 35 40.
14. Toole B.P., Wight T.N., Tammi M.I. (2002) Hyaluronan-cell interactions in cancer and vascular disease. J Biol Chem 277 : 4593 4596.
15. Chen W.Y., Abatangelo G. (1999) Functions of hyaluronan in wound repair. Wound Repair Regen 7 : 79 89.
16. Laurent T.C., Laurent U.B., Fraser J.R. (1996) The structure and function of hyaluronan: an overview. Immunol Cell Biol 74 : A1 A7.
17. Stern R. (2008) Association between cancer and "acid mucopolysaccharides": an old concept comes of age, finally. Semin Cancer Biol 18 : 238 243.
18. Aruffo A., Stamenkovic I., Melnick M., Underhill C.B., Seed B. (1990) CD44 is the principal cell surface receptor for hyaluronate. Cell 61 : 1303 1313.
19. Heldin P., Karousou E., Bernert B., Porsch H., Nishitsuka K., Skandalis S.S. (2008) Importance of hyaluronan-CD44 interactions in inflammation and tumorigenesis. Connect Tissue Res 49 : 215 218.
20. Turley E.A., Noble P.W., Bourguignon L.Y.W. (2002) Signaling properties of hyaluronan receptors. J Biol Chem 277 : 4589 4592.
21. Lehninger A.L., Nelson D.L., Cox M.M. (2004) Principles of Biochemistry 4e. New York : W.H. Freeman & Company p. 238 271.
22. Linhardt R.J., Gunay N.S. (1999) Production and chemical processing of low molecular weight heparins. Semin Thromb Hemost 25 : 5 16.
23. Wardrop D., Keeling D. (2008) The story of the discovery of heparin and warfarin. Br J Haematol 141 : 757 763.
24. Marcum J.A. (2000) The origin of the dispute over the discovery of heparin. J Hist Med Allied Sci 55 : 37 66.
25. Iozzo R.V., San Antonio J.D. (2001) Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J Clin Invest 108 : 349 355.
26. Holt C.E., Dickson B.J. (2005) Sugar codes for axons? Neuron 46 : 169 172.
27. Liu D., Shriver Z., Qi Y., Venkataraman G., Sasisekharan R. (2002) Dynamic regulation of tumor growth and metastasis by heparan sulfate glycosaminoglycans. Semin Thromb Hemost 28 : 67 78.
28. Tímár J., Lapis K., Dudás J., Sebestyén A., Kopper L., Kovalszky I. (2002) Proteoglycans and tumor progression: Janus-faced molecules with contradictory functions in cancer. Semin Cancer Biol 12 : 173 186.
29. Sanderson R.D. (2001) Heparan sulfate proteoglycans in invasion and metastasis. Semin Cell Dev Biol 12 : 89 98.
30. Casu B., Guerrini M., Torri G. (2004) Structural and conformational aspects of the anticoagulant and anti-thrombotic activity of heparin and dermatan sulfate. Curr Pharm Des 10 : 939 949.
31. Fareed J., Hoppensteadt D.A., Bick R.L. (2000) An update on heparins at the beginning of the new millennium. Semin Thromb Hemost 26 : 5 18.
32. Sasisekharan R., Shriver Z., Venkataraman G., Narayanasami U. (2002) Roles of heparan-sulphate glycosaminoglycans in cancer. Nat Rev Cancer 2 : 521 528.
33. Yip G.W., Smollich M., Gotte M. (2006) Therapeutic value of glycosaminoglycans in cancer. Mol Cancer Ther 5 : 2139 2148.
34. Bandtlow C.E., Zimmermann D.R. (2000) Proteoglycans in the developing brain: new conceptual insights for old proteins. Physiol Rev 80 : 1267 1290.
35. Kisilevsky R., Ancsin J.B., Szarek W.A., Petanceska S. (2007) Heparan sulfate as a therapeutic target in amyloidogenesis: prospects and possible complications. Amyloid 14 : 21 32.
36. Snow A.D., Willmer J., Kisilevsky R. (1987) Sulfated glycosaminoglycans: a common constituent of all amyloids? Lab Invest 56 : 120 123.
37. Ley K., Laudanna C., Cybulsky M.I., Nourshargh S. (2007) Getting to the site of inflammation: the leukocyte adhesion cascade updated. Nat Rev Immunol 7 : 678 689.
38. Fry E.E., Lea S.M., Jackson T., Newman J.W.I., Ellard F.M., Blakemore W.E. et al. (1999) The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J 18 : 543 554.
39. Rostand K.S., Esko J.D. (1997) Microbial adherence to and invasion through proteoglycans. Infect Immun 65 : 1 8.
40. Rider C.C. (1997) The potential for heparin and its derivatives in the therapy and prevention of HIV-1 infection. Glycoconj J 14 : 639 642.
41. Rider C.C., Coombe D.R., Harrop H.A., Hounsell E.F., Bauer C., Feeney J. et al. (1994) Anti-HIV-1 activity of chemically modified heparins: correlation between binding to the V3 loop of gp120 and inhibition of cellular HIV-1 infection in vitro. Biochemistry 33 : 6974 6980.
42. Spear P.G., Shieh M.T., Herold B.C., WuDunn D., Koshy T.I. (1992) Heparan sulfate glycosaminoglycans as primary cell surface receptors for herpes simplex virus. Adv Exp Med Biol 313 : 341 353.
43. Shieh M.T., WuDunn D., Montgomery R.I., Esko J.D., Spear P.G. (1992) Cell surface receptors for herpes simplex virus are heparan sulfate proteoglycans. J Cell Biol 116 : 1273 1281.
44. Spear P.G., Eisenberg R.J., Cohen G.H. (2000) Three classes of cell surface receptors for Alphaherpesvirus entry. Virology 275 : 1 8.
45. Patricia G.S. (2004) Herpes simplex virus: receptors and ligands for cell entry. Cell Microbiol 6 : 401 410.
46. Shukla D., Spear P.G. (2001) Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. J Clin Invest 108 : 503 510.
47. Kokenyesi R., Bernfield M. (1994) Core protein structure and sequence determine the site and presence of heparan sulfate and chondroitin sulfate on syndecan-1. J Biol Chem 269 : 12304 12309.
48. Varki A. (1999) The Essentials of Glycobiology. Cold Spring Harbor, New York : Cold Spring Harbor Laboratory Press.
49. Bernfield M., Gotte M., Park P.W., Reizes O., Fitzgerald M.L., Lincecum J. et al. (1999) Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem 68 : 729 777.
50. Iozzo R.V., Cohen I.R., Grassel S., Murdoch A.D. (1994) The biology of perlecan: the multifaceted heparan sulphate proteoglycan of basement membranes and pericellular matrices. Biochem J 302 : 625 639.
51. Nader H.B., Chavante S.F., dos-Santos E.A., Oliveira F.W., de-Paiva J.F., Jerônimo S.M.B. et al. (1999) Heparan sulfates and heparins: similar compounds performing the same functions in vertebrates and invertebrates? Braz J Med Biol Res 32 : 529 538.
52. Warda M., Mao W., Toida T., Linhardt R.J. (2003) Turkey intestine as a commercial source of heparin? Comparative structural studies of intestinal avian and mammalian glycosaminoglycans. Comp Biochem Physiol B Biochem Mol Biol 134 : 189 197.
53. Ototani N., Kikuchi M., Yosizawa Z. (1981) Comparative studies on the structures of highly active and relatively inactive forms of whale heparin. J Biochem 90 : 241 246.
54. Warda M., Gouda E.M., Toida T., Chi L., Linhardt R.J. (2003) Isolation and characterization of raw heparin from dromedary intestine: evaluation of a new source of pharmaceutical heparin. Comp Biochem Physiol C Toxicol Pharmacol 136 : 357 365.
55. Bland C.E., Ginsburg H., Silbert J.E., Metcalfe D.D. (1982) Mouse heparin proteoglycan. Synthesis by mast cell-fibroblast monolayers during lymphocyte-dependent mast cell proliferation. J Biol Chem 257 : 8661 8666.
56. Linhardt R.J., Ampofo S.A., Fareed J., Hoppensteadt D., Folkman J., Mulliken J.B. (1992) Isolation and characterization of human heparin. Biochemistry 31 : 12441 12445.
57. Hovingh P., Linker A. (1982) An unusual heparan sulfate isolated from lobsters (Homarus americanus). J Biol Chem 257 : 9840 9844.
58. Dietrich C.P., Paiva J.F., Castro R.A.B., Chavante S.F., Jeske W., Fareed J. et al. (1999) Structural features and anticoagulant activities of a novel natural low molecular weight heparin from the shrimp Penaeus brasiliensis. Biochim Biophys Acta 1428 : 273 283.
59. Hovingh P., Linker A. (1993) Glycosaminoglycans in Anodonta californiensis, a freshwater mussel. Biol Bull 185 : 263 276.
60. Pejler G., Danielsson A., Bjork I., Lindahl U., Nader H.B., Dietrich C.P. (1987) Structure and antithrombin-binding properties of heparin isolated from the clams Anomalocardia brasiliana and Tivela mactroides. J Biol Chem 262 : 11413 11421.
61. Medeiros G.F., Mendes A., Castro R.A.B., Baú E.C., Nader H.B., Dietrich C.P. (2000) Distribution of sulfated glycosaminoglycans in the animal kingdom: widespread occurrence of heparin-like compounds in invertebrates. Biochim Biophys Acta 1475 : 287 294.
62. Lindahl U., Kjellen L. (1991) Heparin or heparan sulfate - what is the difference? Thromb Haemost 66 : 44 48.
63. Lindahl U., Kjellen L. (1991) Heparin or heparan sulfate - what is the difference? Thromb Haemost 66 : 44 48.
64. Lyon M., Gallagher J.T. (1998) Bio-specific sequences and domains in heparan sulphate and the regulation of cell growth and adhesion. Matrix Biol 17 : 485 493.
65. Spillmann D., Witt D., Lindahl U. (1998) Defining the interleukin-8-binding domain of heparan sulfate. J Biol Chem 273 : 15487 15493.
66. Stringer S.E., Gallagher J.T. (1997) Specific binding of the chemokine platelet factor 4 to heparan sulfate. J Biol Chem 272 : 20508 20514.
67. Stringer S.E., Forster M.J., Mulloy B., Bishop C.R., Graham G.J., Gallagher J.T. (2002) Characterization of the binding site on heparan sulfate for macrophage inflammatory protein 1alpha. Blood 100 : 1543.
68. Krieger E., Geretti E., Brandner B., Goger B., Wells T.N., Kungl A.J. (2004) A structural and dynamic model for the interaction of interleukin-8 and glycosaminoglycans: support from isothermal fluorescence titrations. Proteins 54 : 768 775.
69. Lortat-Jacob H., Turnbull J.E., Grimaud J.A. (1995) Molecular organization of the interferon gamma-binding domain in heparan sulphate. Biochem J 310 : 497 505.
70. Lohse D.L., Linhardt R.J. (1992) Purification and characterization of heparin lyases from Flavobacterium heparinum. J Biol Chem 267 : 24347 24355.
71. Linhardt R.J., Turnbull J.E., Wang H.M., Loganathan D., Gallagher J.T. (1990) Examination of the substrate specificity of heparin and heparan sulfate lyases. Biochemistry 29 : 2611 2617.
72. Desai U.R., Wang H.M., Linhardt R.J. (1993) Specificity studies on the heparin lyases from Flavobacterium heparinum. Biochemistry 32 : 8140 8145.
73. Wu Z.L., Lech M. (2005) Characterizing the non-reducing end structure of heparan sulfate. J Biol Chem 280 : 33749 33755.
74. Pikas D.S., Li J.-p., Vlodavsky I., Lindahl U. (1998) Substrate specificity of heparanases from human hepatoma and platelets. J Biol Chem 273 : 18770 18777.
75. Bishop J.R., Schuksz M., Esko J.D. (2007) Heparan sulphate proteoglycans fine-tune mammalian physiology. Nature 446 : 1030 1037.
76. Lindahl U., Kusche-Gullberg M., Kjellen L. (1998) Regulated diversity of heparan sulfate. J Biol Chem 273 : 24979 24982.
77. Ferro D.R., Provasoli A., Ragazzi M., Casu B., Torri G., Bossennec V. et al. (1990) Conformer populations of l-iduronic acid residues in glycosaminoglycan sequences. Carbohydr Res 195 : 157 167.
78. Ferro D.R., Provasoli A., Ragazzi M., Torri G., Casu B., Gatti G. et al. (1986) Evidence for conformational equilibrium of the sulfated l-iduronate residue in heparin and in synthetic heparin mono-and oligo-saccharides: NMR and force-field studies. J Am Chem Soc 108 : 6773 6778.
79. Mulloy B., Forster M.J., Jones C., Davies D.B. (1993) NMR and molecular-modelling studies of the solution conformation of heparin. Biochem J 293 : 849 858.
80. Desai U.R., Wang H.M., Kelly T.R., Linhardt R.J. (1993) Structure elucidation of a novel acidic tetrasaccharide and hexasaccharide derived from a chemically modified heparin. Carbohydr Res 241 : 249 259.
81. Yates E.A., Santini F., Guerrini M., Naggi A., Torri G., Casu B. (1996) 1H and 13C NMR spectral assignments of the major sequences of twelve systematically modified heparin derivatives. Carbohydr Res 294 : 15 27.
82. Ragazzi M., Ferro D.R., Provasoli A., Pumilia P., Cassinari A., Torri G. et al. (1993) Conformation of the unsaturated uronic acid residues of glycosamtnoglycan disaccharides. J Carbohydr Chem 12 : 523 535.
83. van Boeckel C.A., van Aelst S.F., Wagenaars G.N., Mellema J.R., Paulsen H., Peters T. et al. (1987) Conformational analysis of synthetic heparin-like oligosaccharides containing {alpha}-l-idopyranosyluronic acid. Recl Trav Chim Pays Bas 106 : 19 29.
84. Mikhailov D., Mayo K.H., Vlahov I.R., Toida T., Pervin A., Linhardt R.J. (1996) NMR solution conformation of heparin-derived tetrasaccharide. Biochem J 318 : 93 102.
85. Mulloy B., Forster M.J., Jones C., Drake A.F., Johnson E.A., Davies D.B. (1994) The effect of variation of substitution on the solution conformation of heparin: a spectroscopic and molecular modelling study. Carbohydr Res 255 : 1 26.
86. DiGabriele A.D., Lax I., Chen D.I., Svahn C.M., Jaye M., Schlessinger J. et al. (1998) Structure of a heparin-linked biologically active dimer of fibroblast growth factor. Nature 393 : 812 817.
87. Hricovíni M., Nieto P.N., Torri G. (2003) NMR of Sulfated Oligo and Polysaccharides. Weinhem, Germany : Wiley-VCH Verlag GmbH & Co. KGaA.
88. Remko M., Swart M., Bickelhaupt F.M. (2007) Conformational behavior of basic monomeric building units of glycosaminoglycans: isolated systems and solvent effect. J Phys Chem B 111 : 2313 2321.
89. Remko M., Hricovíni M. (2007) Theoretical study of structure and properties of hexuronic acid and d-glucosamine structural units of glycosaminoglycans. Struct Chem 18 : 537 547.
90. Mulloy B., Forster M.J. (2000) Conformation and dynamics of heparin and heparan sulfate. Glycobiology 10 : 1147 1156.
91. Faham S., Hileman R.E., Fromm J.R., Linhardt R.J., Rees D.C. (1996) Heparin structure and interactions with basic fibroblast growth factor. Science 271 : 1116.
92. Capila I., Hernáiz M.J., Mo Y.D., Mealy T.R., Campos B., Dedman J.R. et al. (2001) Annexin V-heparin oligosaccharide complex suggests heparan sulfate-mediated assembly on cell surfaces. Structure 9 : 57 64.
93. Jin L., Abrahams J.P., Skinner R., Petitou M., Pike R.N., Carrell R.W. (1997) The anticoagulant activation of antithrombin by heparin. Proc Natl Acad Sci USA 94 : 14683 14688.
94. Ragazzi M., Ferro D.R., Perly B., Sinay P., Petitou M., Choay J. (1990) Conformation of the pentasaccharide corresponding to the binding site of heparin for antithrombin III. Carbohydr Res 195 : 169 185.
95. Ragazzi M., Ferro D.R., Provasoli A. (1986) A force-field study of the conformational characteristics of the iduraonate ring. J Comput Chem 7 : 105 112.
96. Hricovini M., Guerrini M., Bisio A. (1999) Structure of heparin-derived tetrasaccharide complexed to the plasma protein antithrombin derived from NOEs, J-couplings and chemical shifts. Eur J Biochem 261 : 789 801.
97. Hricovini M., Guerrini M., Bisio A., Torri G., Petitou M., Casu B. (2001) Conformation of heparin pentasaccharide bound to antithrombin III. Biochem J 359 : 265 272.
98. Hricovini M., Guerrini M., Bisio A., Torri G., Naggi A., Casu B. (2002) Active conformations of glycosaminoglycans. NMR determination of the conformation of heparin sequences complexed with antithrombin and fibroblast growth factors in solution. Semin Thromb Hemost 28 : 325 334.
99. Guerrini M., Guglieri S., Beccati D., Torri G., Viskov C., Mourier P. (2006) Conformational transitions induced in heparin octasaccharides by binding with antithrombin III. Biochem J 399 : 191 198.
100. Sasisekharan R., Raman R., Prabhakar V. (2006) Glycomics approach to structure-function relationships of glycosaminoglycans. Annu Rev Biomed Eng 8 : 181 231.
101. Malik A., Ahmad S. (2007) Sequence and structural features of carbohydrate binding in proteins and assessment of predictability using a neural network. BMC Struct Biol 7 : 1.
102. Shionyu-Mitsuyama C., Shirai T., Ishida H., Yamane T. (2003) An empirical approach for structure-based prediction of carbohydrate-binding sites on proteins. Protein Eng Des Sel 16 : 467 478.
103. Taroni C., Jones S., Thornton J.M. (2000) Analysis and prediction of carbohydrate binding sites. Protein Eng Des Sel 13 : 89 98.
104. Fromm J.R., Hileman R.E., Caldwell E.E.O., Weiler J.M., Linhardt R.J. (1997) Pattern and spacing of basic amino acids in heparin binding sites. Arch Biochem Biophys 343 : 92 100.
105. Hileman R.E., Fromm J.R., Weiler J.M., Linhardt R.J. (1998) Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. BioEssays 20 : 156 167.
106. Caldwell E.E., Nadkarni V.D., Fromm J.R., Linhardt R.J., Weiler J.M. (1996) Importance of specific amino acids in protein binding sites for heparin and heparan sulfate. Int J Biochem Cell Biol 28 : 203 216.
107. Thompson L.D., Pantoliano M.W., Springer B.A. (1994) Energetic characterization of the basic fibroblast growth factor-heparin interaction: identification of the heparin binding domain. Biochemistry 33 : 3831 3840.
108. Bae J., Desai U.R., Pervin A., Caldwell E.E., Weiler J.M., Linhardt R.J. (1994) Interaction of heparin with synthetic antithrombin III peptide analogues. Biochem J 301 : 121 129.
109. Jairajpuri M.A., Lu A., Desai U., Olson S.T., Bjork I., Bock S.C. (2003) Antithrombin III phenylalanines 122 and 121 contribute to its high affinity for heparin and its conformational activation. J Biol Chem 278 : 15941 15950.
110. Arocas V., Bock S.C., Olson S.T., Bjork I. (1999) The role of Arg46 and Arg47 of antithrombin in heparin binding. Biochemistry 38 : 10196 10204.
111. Desai U., Swanson R., Bock S.C., Bjork I., Olson S.T. (2000) Role of arginine 129 in heparin binding and activation of antithrombin. J Biol Chem 275 : 18976 18984.
112. Schedin-Weiss S., Desai U.R., Bock S.C., Gettins P.G., Olson S.T., Bjork I. (2002) Importance of lysine 125 for heparin binding and activation of antithrombin. Biochemistry 41 : 4779 4788.
113. Arocas V., Bock S.C., Raja S., Olson S.T., Bjork I. (2001) Lysine 114 of antithrombin is of crucial importance for the affinity and kinetics of heparin pentasaccharide binding. J Biol Chem 276 : 43809 43817.
114. Guo N.H., Krutzsch H.C., NÃ̈gre E., Vogel T., Blake D.A., Roberts D.D. (1992) Heparin- and sulfatide-binding peptides from the type I repeats of human thrombospondin promote melanoma cell adhesion. Proc Natl Acad Sci USA 89 : 3040 3044.
115. Woods A., McCarthy J.B., Furcht L.T., Couchman J.R. (1993) A synthetic peptide from the COOH-terminal heparin-binding domain of fibronectin promotes focal adhesion formation. Mol Biol Cell 4 : 605 613.
116. Cardin A.D., Weintraub H.J. (1989) Molecular modeling of protein-glycosaminoglycan interactions. Arterioscler Thromb Vasc Biol 9 : 21 32.
117. Margalit H., Fischer N., Ben-Sasson S.A. (1993) Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues. J Biol Chem 268 : 19228 19231.
118. Silvian L., Jin P., Carmillo P., Boriack-Sjodin P.A., Pelletier C., Rushe M. et al. (2006) Artemin crystal structure reveals insights into heparan sulfate binding. Biochemistry 45 : 6801 6812.
119. Vyas A.A., Pan J.J., Patel H.V., Vyas K.A., Chiang C.M., Sheu Y.C. et al. (2005) Analysis of binding of cobra cardiotoxins to heparin reveals a new beta-sheet heparin-binding structural motif. J Biol Chem 280 : 9567 9577.
120. Sobel M., Soler D.F., Kermode J.C., Harris R.B. (1992) Localization and characterization of a heparin binding domain peptide of human von Willebrand factor. J Biol Chem 267 : 8857 8862.
121. Johnson Z., Power C.A., Weiss C., Rintelen F., Ji H., Ruckle T. et al. (2004) Chemokine inhibition - why, when, where, which and how. Biochem Soc Trans 32 : 366 377.
122. Kuschert G.S., Coulin F., Power C.A., Proudfoot A.E., Hubbard R.E., Hoogewerf A.J. et al. (1999) Glycosaminoglycans interact selectively with chemokines and modulate receptor binding and cellular responses. Biochemistry 38 : 12959 12968.
123. Mulloy B., Crane D.T., Drake A.F., Davies D.B. (1996) The interaction between heparin and polylysine: a circular dichroism and molecular modelling study. Braz J Med Biol Res 29 : 721 729.
124. Sibille N., Sillen A., Leroy A., Wieruszeski J.M., Mulloy B., Landrieu I. et al. (2006) Structural impact of heparin binding to full-length Tau as studied by NMR spectroscopy. Biochemistry 45 : 12560 12572.
125. Rusnati M., Coltrini D., Oreste P., Zoppetti G., Albini A., Noonan D. et al. (1997) Interaction of HIV-1 Tat protein with heparin. Role of the backbone structure, sulfation and size. J Biol Chem 272 : 11313 11320.
126. Olson S.T., Chuang Y.-J. (2002) Heparin activates antithrombin anticoagulant function by generating new interaction sites (exosites) for blood clotting proteinases. Trends Cardiovasc Med 12 : 331 338.
127. Petitou M., Duchaussoy P., Driguez P.A., Jaurand G., Herault J.P., Lormeau J.C. et al. (1998) First synthetic carbohydrates with the full antocoagulant properties of heparin. Angew Chem Int Ed Engl 37 : 3009 3014.
128. Schlessinger J., Plotnikov A.N., Ibrahimi O.A., Eliseenkova A.V., Yeh B.K., Yayon A. et al. (2000) Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell 6 : 743 750.
129. Rusnati M., Coltrini D., Caccia P., Dell'Era P., Zoppetti G., Oreste P. et al. (1994) Distinct role of 2-O-, N-, and 6-O-sulfate groups of heparin in the formation of the ternary complex with basic fibroblast growth factor and soluble FGF receptor-1. Biochem Biophys Res Commun 203 : 450 458.
130. Pellegrini L., Burke D.F., von Delft F., Mulloy B., Blundell T.L. (2000) Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin. Nature 407 : 1029 1034.
131. Canales A., Angulo J., Ojeda R., Bruix M., Fayos R., Lozano R. et al. (2005) Conformational flexibility of a synthetic glycosylaminoglycan bound to a fibroblast growth factor. FGF-1 recognizes both the (1) C (4) and (2) S (O) conformations of a bioactive heparin-like hexasaccharide. J Am Chem Soc 127 : 5778 5779.
132. Fraser P.E., Nguyen J.T., Surewicz W.K., Kirschner D.A. (1991) pH-dependent structural transitions of Alzheimer amyloid peptides. Biophys J 60 : 1190 1201.
133. Arteel G.E., Franken S., Kappler J., Sies H. (2000) Binding of Selenoprotein P to heparin: characterization with surface plasmon resonance. Biol Chem 381 : 265 268.
134. Wettreich A., Sebollela A., Carvalho M.A., Azevedo S.P., Borojevic R., Ferreira S.T. et al. (1999) Acidic pH modulates the interaction between human granulocyte-macrophage colony-stimulating factor and glycosaminoglycans. J Biol Chem 274 : 31468 31475.
135. Matsumoto R. (1995) Packaging of proteases and proteoglycans in the granules of mast cells and other hematopoietic cells. J Biol Chem 270 : 19524 19531.
136. Veldkamp C.T., Peterson F.C., Pelzek A.J., Volkman B.F. (2005) The monomer-dimer equilibrium of stromal cell-derived factor-1 (CXCL 12) is altered by pH, phosphate, sulfate, and heparin. Protein Sci 14 : 1071 1081.
137. Gandhi N.S., Coombe D.R., Mancera R.L. (2008) Platelet endothelial cell adhesion molecule 1 (PECAM-1) and its interactions with glycosaminoglycans: 1. Molecular modeling studies. Biochemistry 47 : 4851 4862.
138. Coombe D.R., Stevenson S.M., Kinnear B.F., Gandhi N.S., Mancera R.L., Osmond R.I.W. et al. (2008) Platelet endothelial cell adhesion molecule 1 (PECAM-1) and its interactions with glycosaminoglycans: 2. Biochemical analyses. Biochemistry 47 : 4863 4875.
139. Hallgren J., Backstrom S., Estrada S., Thuveson M., Pejler G. (2004) Histidines are critical for heparin-dependent activation of mast cell tryptase 1. J Immunol 173 : 1868 1875.
140. Borza D.B., Morgan W.T. (1998) Histidine-proline-rich glycoprotein as a plasma pH sensor. Modulation of its interaction with glycosaminoglycans by pH and metals. J Biol Chem 273 : 5493 5499.
141. Chevalier F., Lucas R., Angulo J., Martin-Lomas M., Nieto P.M. (2004) The heparin-Ca (2+) interaction: the influence of the O-sulfation pattern on binding. Carbohydr Res 339 : 975 983.
142. 2+ binding site. Eur J Org Chem 2367 : 2376.
143. Shao C., Zhang F., Kemp M.M., Linhardt R.J., Waisman D.M., Head J.F. et al. (2006) Crystallographic analysis of calcium-dependent heparin binding to Annexin A2. J Biol Chem 281 : 31689 31695.
144. Ricard-Blum S., Feraud O., Lortat-Jacob H., Rencurosi A., Fukai N., Dkhissi F. et al. (2004) Characterization of endostatin binding to heparin and heparan sulfate by surface plasmon resonance and molecular modeling: role of divalent cations. J Biol Chem 279 : 2927.
145. Gonza'lez-Iglesias R., Pajares M.A., Ocal C., Oesch B., Gasset M. (2002) Prion protein interaction with glycosaminoglycan occurs with the formation of oligomeric complexes stabilized by Cu (II) bridges. J Mol Biol 319 : 527 540.
146. 2+. Arch Biochem Biophys 170 : 334 340.
147. Parrish R.F., Fair W.R. (1981) Selective binding of zinc ions to heparin rather than to other glycosaminoglycans. Biochem J 193 : 407 410.
148. Whitfield D.M., Choay J., Sarkar B. (1992) Heavy metal binding to heparin disaccharides. I. Iduronic acid is the main binding site. Biopolymers 32 : 585 596.
149. Whitfield D.M., Sarkar B. (1992) Heavy metal binding to heparin disaccharides. II. First evidence for zinc chelation. Biopolymers 32 : 597 619.
150. Imberty A., Lortat-Jacob H., Pérez S. (2007) Structural view of glycosaminoglycan-protein interactions. Carbohydr Res 342 : 430 439.
151. Lortat-Jacob H., Grosdidier A., Imberty A. (2002) Structural diversity of heparan sulfate binding domains in chemokines. Proc Natl Acad Sci USA 99 : 1229 1234.
152. Goodford P.J. (1985) A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 28 : 849 857.
153. Bitomsky W., Wade R.C. (1999) Docking of glycosaminoglycans to heparin-binding proteins: validation for aFGF, bFGF, and antithrombin and application to IL-8. J Am Chem Soc 121 : 3004 3013.
154. Mulloy B., Forster M.J. (2008) Application of drug discovery software to the identification of heparin-binding sites on protein surfaces: a computational survey of the 4-helix cytokines. Mol Simul 34 : 481 489.
155. Fallahi A., Kroll B., Warner L.R., Oxford R.J., Irwin K.M., Mercer L.M. et al. (2005) Structural model of the amino propeptide of collagen XI {alpha}1 chain with similarity to the LNS domains. Protein Sci 14 : 1526 1537.
156. da.Rocha P.S.S., Tácio V., Amorim F., Raul C.E., Geraldo P.P. (2008) Studies of molecular docking between fibroblast growth factor and heparin using generalized simulated annealing. Int J Quantum Chem 108 : 2608 2614.
157. Forster M., Mulloy B. (2006) Computational approaches to the identification of heparin-binding sites on the surfaces of proteins. Biochem Soc Trans 34 : 431 434.
158. Kern A., Schmidt K., Leder C., Muller O.J., Wobus C.E., Bettinger K. et al. (2003) Identification of a heparin-binding motif on adeno-associated virus type 2 capsids. J Virol 77 : 11072 11081.
159. Lam K., Rao V.S., Qasba P.K. (1998) Molecular modeling studies on binding of bFGF to heparin and its receptor FGFR1. J Biomol Struct Dyn 15 : 1009 1027.
160. Sadir R., Baleux F., Grosdidier A., Imberty A., Lortat-Jacob H. (2001) Characterization of the stromal cell-derived factor-1a-heparin complex. J Biol Chem 276 : 8288 8296.
161. Grootenhuis P.D.J., Van Boeckel C.A.A. (1991) Constructing a molecular model of the interaction between antithrombin III and a potent heparin analog. J Am Chem Soc 113 : 2743 2747.
162. Canales A., Lozano R., Lopez-Mendez B., Angulo J., Ojeda R., Nieto P.M. et al. (2006) Solution NMR structure of a human FGF-1 monomer, activated by a hexasaccharide heparin-analogue. FEBS J 273 : 4716.
163. Raghuraman A., Mosier P.D., Desai U.R. (2006) Finding a needle in a haystack: development of a combinatorial virtual screening approach for identifying high specificity heparin/heparan sulfate sequence (s). J Med Chem 49 : 3553 3562.
164. Nicolaes G.A.F., rensen K.W., Friedrich U., Tans G., Rosing J., Autin L. et al. (2004) Altered inactivation pathway of factor Va by activated protein C in the presence of heparin. Eur J Biochem 271 : 2724 2736.
165. Keserü G.M., Kolossváry I. (1999) Molecular Mechanics and Conformational Analysis in Drug Design. Oxford, UK : Blackwell Publishing.
166. Cochran S., Li C.P., Bytheway I. (2005) An experimental and molecular-modeling study of the binding of linked sulfated tetracyclitols to FGF-1 and FGF-2. Chembiochem 6 : 1882 1890.
167. Kerzmann A., Neumann D., Kohlbacher O. (2006) SLICK-scoring and energy functions for protein-carbohydrate interactions. J Chem Inf Model 46 : 1635 1642.
168. Laederach A., Reilly P.J. (2003) Specific empirical free energy function for automated docking of carbohydrates to proteins. J Comput Chem 24 : 1748 1757.
169. Liu L., Bytheway I., Karoli T., Fairweather J.K., Cochran S., Li C. et al. (2008) Design, synthesis, FGF-1 binding, and molecular modeling studies of conformationally flexible heparin mimetic disaccharides. Bioorg Med Chem Lett 18 : 344 349.
170. Bytheway I., Cochran S. (2004) Validation of molecular docking calculations involving FGF-1 and FGF-2. J Med Chem 47 : 1683 1693.
171. Mitchell J.B.O., Laskowski R.A., Alex A., Thornton J.M. (1999) BLEEP - potential of mean force describing protein-ligand interactions: I. Generating potential. J Comput Chem 20 : 1165 1176.
172. Aqvist J., Marelius J. (2001) The linear interaction energy method for predicting ligand binding free energies. Comb Chem High Throughput Screen 4 : 613 626.
173. Laitinen T., Rouvinen J., Peräkylä M. (2003) MM-PBSA free energy analysis of endo-1, 4-xylanase II (XynII)-substrate complexes: binding of the reactive sugar in a skew boat and chair conformation. Org Biomol Chem 1 : 3535 3540.
174. Verli H., Guimarães J.A. (2005) Insights into the induced fit mechanism in antithrombin-heparin interaction using molecular dynamics simulations. J Mol Graph Model 24 : 203 212.
175. Verli H., Guimarães J.A. (2004) Molecular dynamics simulation of a decasaccharide fragment of heparin in aqueous solution. Carbohydr Res 339 : 281 290.
176. Pol-Fachin L., Verli H. (2008) Depiction of the forces participating in the 2-O-sulfo-[alpha]-l-iduronic acid conformational preference in heparin sequences in aqueous solutions. Carbohydr Res 343 : 1435 1445.
177. Kony D., Damm W., Stoll S., Gunsteren W.F.V. (2002) An improved OPLS-AA force field for carbohydrates. J Comput Chem 23 : 1416 1429.
178. Lins R.D., Hünenberger P.H. (2005) A new GROMOS force field for hexopyranose-based carbohydrates. J Comput Chem 26 : 1400 1412.
179. Kuttel M., Brady J.W., Naidoo K.J. (2002) Carbohydrate solution simulations: producing a force field with experimentally consistent primary alcohol rotational frequencies and populations. J Comput Chem 23 : 1236 1243.
180. Brooks B.R., Bruccoleri R.E., Olafson B.D., States D.J., Swaminathan S., Karplus M. (1983) CHARMM: a program for macromolecular energy, minimization, and dynamics calculations. J Comput Chem 4 : 187 217.
181. Grootenhuis P.D.J., Haasnoot C.A.G. (1993) A CHARMm based force field for carbohydrates using the CHEAT approach: carbohydrate hydroxyl groups represented by extended atoms. Mol Simul 10 : 75 95.
182. Woods R.J., Dwek R.A., Edge C.J., Fraser-Reid B. (1995) Molecular mechanical and molecular dynamic simulations of glycoproteins and oligosaccharides. 1. GLYCAM_93 parameter development. J Phys Chem 99 : 3832 3846.
183. Allinger N.L. (1977) Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms. J Am Chem Soc 99 : 8127 8134.
184. Allinger N.L., Yuh Y.H., Lii J.H. (1989) Molecular mechanics. The MM3 force field for hydrocarbons. 1. J Am Chem Soc 111 : 8551 8566.
185. Fabricius J., Engelsen S.B., Rasmussen K. (1997) The Consistent Force Field. 5. PEF95SAC: optimized potential energy function for alcohols and carbohydrates. J Carbohydr Chem 16 : 751 772.
186. Imberty A., Bettler E., Karababa M., Mazeau K., Petrova P., Pérez S. (1999) Building Sugars: The Sweet Part of Structural Biology. Hyderabad : Perspectives in Structural Biology Indian Academy of Sciences and Universities Press p. 392 409.
187. Ferro D.R., Pumilia P., Cassinari A., Ragazzi M. (1995) Treatment of ionic species in force-field calculations: sulfate and carboxylate groups in carbohydrates. Int J Biol Macromol 17 : 131 136.
188. Ferro D.R., Pumilia P., Ragazzi M. (1997) An improved force field for conformational analysis of sulfated polysaccharides. J Comput Chem 18 : 351 367.
189. Huige C.J.M., Altona C. (1995) Force field parameters for sulfates and sulfamates based on Ab initio calculations: extensions of AMBER and CHARMm fields. J Comput Chem 16 : 56 79.
190. Kirschner K.N., Yongye A.B., Tschampel S.M., Gonzalez-Outeirino J., Daniels C.R., Foley B.L. et al. (2008) GLYCAM06: a generalizable biomolecular force field. Carbohydrates. J Comput Chem 29 : 622 655.
191. Jin L. (2007) PhD Thesis : University of Edinburgh.
192. Lindahl U. (2007) Heparan sulfate-protein interactions - a concept for drug design? Thromb Haemost 98 : 109 115.
193. Fugedi P. (2003) The potential of the molecular diversity of heparin and heparan sulfate for drug development. Mini Rev Med Chem 3 : 659 667.
194. Johnson Z., Proudfoot A.E., Handel T.M. (2005) Interaction of chemokines and glycosaminoglycans: a new twist in the regulation of chemokine function with opportunities for therapeutic intervention. Cytokine Growth Factor Rev 16 : 625 636.
195. Spillmann D., Lindahl U. (1994) Glycosaminoglycan-protein interactions: a question of specificity. Curr Opin Struct Biol 4 : 677 682.
196. Coombe D.R. (2008) Biological implications of glycosaminoglycan interactions with haemopoietic cytokines. Immunol Cell Biol 86 : 598 607.
197. Webb L.M., Ehrengruber M.U., Clark-Lewis I., Baggiolini M., Rot A. (1993) Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. Proc Natl Acad Sci USA 90 : 7158 7162.
198. Codée J.D.C., Overkleeft H.S., van der Marel G.A., van Boeckel C.A.A. (2004) The synthesis of well-defined heparin and heparan sulfate fragments. Drug Discov Today: Technol 1 : 317 326.
199. Choay J., Petitou M., Lormeau J.C., Sinay P., Casu B., Gatti G. (1983) Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 116 : 492 499.
200. Johnson D.J.D., Li W., Adams T.E., Huntington J.A. (2006) Antithrombin-S195A factor Xa-heparin structure reveals the allosteric mechanism of antithrombin activation. EMBO J 25 : 2029 2037.
201. Tan K., Duquette M., Liu J.-h., Zhang R., Joachimiak A., Wang J.-h. et al. (2006) The structures of the thrombospondin-1 N-terminal domain and its complex with a synthetic pentameric heparin. Structure 14 : 33 42.
202. Petitou M., van Boeckel C.A.A. (2004) A synthetic antithrombin III binding pentasaccharide is now a drug! What comes next. Angew Chem Int Ed Engl 43 : 3118 3133.
203. Herbert J.M., Herault J.P., Bernat A., van Amsterdam R.G.M., Lormeau J.C., Petitou M. et al. (1998) Biochemical and pharmacological properties of SANORG 34006, a potent and long-acting synthetic pentasaccharide. Blood 91 : 4197.
204. Li W., Johnson D.J., Esmon C.T., Huntington J.A. (2004) Structure of the antithrombin-thrombin-heparin ternary complex reveals the antithrombotic mechanism of heparin. Nat Struct Mol Biol 11 : 857 862.
205. Ferro V., Don R. (2003) The development of the novel angiogenesis inhibitor PI-88 as an anticancer drug. Australas Biotechnol 13 : 38 39.
206. Wall D., Douglas S., Ferro V., Cowden W., Parish C. (2001) Characterisation of the anticoagulant properties of a range of structurally diverse sulfated oligosaccharides. Thromb Res 103 : 325 335.
207. Freeman C., Liu L., Banwell M.G., Brown K.J., Bezos A., Ferro V. et al. (2005) Use of sulfated linked cyclitols as heparan sulfate mimetics to probe the heparin/heparan sulfate binding specificity of proteins. J Biol Chem 280 : 8842 8849.
208. Raghuraman A., Riaz M., Hindle M., Desai U.R. (2007) Rapid and efficient microwave-assisted synthesis of highly sulfated organic scaffolds. Tetrahedron Lett 48 : 6754 6758.
209. Yamaguchi M., Ohmori T., Sakata Y., Ueki M. (2008) Oligo(tyrosine sulfate)s as heparin pentasaccharide mimic: evaluation by surface noncovalent affinity mass spectrometry. Bioorg Med Chem 16 : 3342 3351.
210. Desai U.R. (2004) New antithrombin-based anticoagulants. Med Res Rev 24 : 151 181.
211. Alban S. (2008) Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des 14 : 1152 1175.
212. Monien B.H., Cheang K.I., Desai U.R. (2005) Mechanism of Poly(acrylic acid) acceleration of antithrombin inhibition of thrombin: implications for the design of novel heparin mimics. J Med Chem 48 : 5360 5368.
213. Monien B.H., Henry B.L., Raghuraman A., Hindle M., Desai U.R. (2006) Novel chemo-enzymatic oligomers of cinnamic acids as direct and indirect inhibitors of coagulation proteinases. Bioorg Med Chem 14 : 7988 7998.
214. Gunnarsson G.T., Desai U.R. (2002) Designing small, nonsugar activators of antithrombin using hydropathic interaction analyses. J Med Chem 45 : 1233 1243.
215. Kellogg G.E., Joshi G.S., Abraham D.J. (1992) New tools for modeling and understanding hydrophobicity and hydrophobic interactions. Med Chem Res 1 : 444 453.
216. Kellogg G.E., Semus S.F., Abraham D.J. (1991) HINT: a new method of empirical hydrophobic field calculation for CoMFA. J Comput Aided Mol Des 5 : 545 552.
217. Gunnarsson G.T., Desai U.R. (2002) Interaction of designed sulfated flavanoids with antithrombin: lessons on the design of organic activators. J Med Chem 45 : 4460 4470.
218. Zhang J., Rivers G., Zhu Y., Jacobson A., Peyers J., Grundstrom G. et al. (2001) Identification of inhibitors of heparin-growth factor interactions from combinatorial libraries of four-component condensation reactions. Bioorg Med Chem 9 : 825 836.
219. Kim S.H., Kiick K.L. (2007) Heparin-mimetic sulfated peptides with modulated affinities for heparin-binding peptides and growth factors. Peptides 28 : 2125 2136.
220. Raghuraman A., Tiwari V., Thakkar J.N., Gunnarsson G.T., Shukla D., Hindle M. et al. (2005) Structural characterization of a serendipitously discovered bioactive macromolecule, lignin sulfate. Biomacromolecules 6 : 2822 2832.
221. Schuksz M., Fuster M.M., Brown J.R., Crawford B.E., Ditto D.P., Lawrence R. et al. (2008) Surfen, a small molecule antagonist of heparan sulfate. Proc Natl Acad Sci USA 105 : 13075 13080.
222. de Paz J.L., Moseman E.A., Noti C., Polito L., von Andrian U.H., Seeberger P.H. (2007) Profiling heparin-chemokine interactions using synthetic tools. ACS Chem Biol 2 : 735 744.
223. de Paz J.L., Noti C., Seeberger P.H. (2006) Microarrays of synthetic heparin oligosaccharides. J Am Chem Soc 128 : 2766 2767.
224. Paz J.L., Seeberger P.H. (2008) Deciphering the glycosaminoglycan code with the help of microarrays. Mol BioSys 4 : 707 711.
225. Seeberger P.H., Werz D.B. (2007) Synthesis and medical applications of oligosaccharides. Nature 446 : 1046.
226. Fernandez C., Hattan C.M., Kerns R.J. (2006) Semi-synthetic heparin derivatives: chemical modifications of heparin beyond chain length, sulfate substitution pattern and N-sulfo/N-acetyl groups. Carbohydr Res 341 : 1253 1265.
227. Huang L., Kerns R.J. (2006) Diversity-oriented chemical modification of heparin: identification of charge-reduced N-acyl heparin derivatives having increased selectivity for heparin-binding proteins. Bioorg Med Chem 14 : 2300 2313.
228. Boulanger M.J., Garcia K.C., Garcia K.C. (2004) Shared Cytokine Signaling Receptors: Structural Insights From the Gp130 System. San Diego, CA, USA : Academic Press p. 107 146.
229. Walter M.R., Garcia K.C. (2004) Structural Analysis of IL-10 and Type I Interferon Family Members and THEIR Complexes with Receptor. San Diego, CA, USA : Academic Press p. 171 223.
230. Lau E.K., Allen S., Hsu A.R., Handel T.M., Garcia K.C. (2004) Chemokine-Receptor Interactions: GPCRs, Glycosaminoglycans and Viral Chemokine Binding Proteins. San Diego, CA, USA : Academic Press p. 351 391.
231. Oppenheim J.J., Feldmann M., Durum S.K. (2001) Cytokine Reference: A Compendium of Cytokines and Other Mediators of Host Defense. San Diego, CA; London : Academic.
232. Ceroni A., Dell A., Haslam S. (2007) The GlycanBuilder: a fast, intuitive and flexible software tool for building and displaying glycan structures. Source Code Biol Med 2 : 3.